{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:25:39Z","timestamp":1787095539982,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Dilated cardiomyopathy (DCM) is a progressive, intractable disease that leads to heart failure. Heart transplantation is the only curative treatment; however, access is limited by donor scarcity. Induced pluripotent stem cell (iPSC)-based therapies are attracting attention for DCM, but suitable large-animal models and robust preclinical data have been limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We generated multi-layered cardiovascular cell sheets from human iPSCs by combining cardiomyocytes with endothelial and stromal cells and overcoming stacking limits using interleaved gelatin hydrogel microspheres, yielding a thicker cardiac tissue-like construct (product code: IHJ-301). To enable rigorous testing in non-ischemic heart failure, we established a modified canine rapid-pacing heart failure model that maintains depressed function without mortality by continuing pacing at a slightly reduced rate after induction (Step-Down Pacing Heart Failure model). IHJ-301 was implanted epicardially onto the left ventricular surface via thoracotomy, and cardiac function was assessed by echocardiography and right-heart catheterization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      After 4 weeks of rapid pacing (230\u2009\u00b1\u200910\u00a0bpm), left ventricular ejection fraction (LVEF) was reduced from 77.8\u2009\u00b1\u20091.1% (pre-pacing) to 44.9\u2009\u00b1\u20091.9% (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) (0\u00a0W). Continued pacing at 210\u2009\u00b1\u200910\u00a0bpm for additional 4 weeks resulted in no mortality and maintained depressed function (4\u00a0W LVEF 47.3\u2009\u00b1\u20092.6%). IHJ-301 was implanted at 0\u00a0W. At 4 weeks post-implantation (4\u00a0W), all animals in the IHJ-301 group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20095) showed greater functional improvement than sham (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20096). Absolute changes from 0\u00a0W to 4\u00a0W were: \u0394LVEF (%) 9.38\u2009\u00b1\u20091.47 vs. 1.90\u2009\u00b1\u20090.34; \u0394fractional shortening (%) 4.84\u2009\u00b1\u20090.75 vs. 0.97\u2009\u00b1\u20090.18; stroke volume (mL\/beat) 1.21\u2009\u00b1\u20091.26 vs. \u22122.99\u2009\u00b1\u20090.60; cardiac output (L\/min) 0.19\u2009\u00b1\u20090.19 vs. \u22120.58\u2009\u00b1\u20090.12 (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.05).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We established a non-ischemic large-animal heart failure model that sustains depressed function for one month, enabling clear therapeutic readouts. IHJ-301 significantly improved multiple parameters of cardiac function, providing preclinical evidence that IHJ-301 could offer a promising therapeutic option for DCM.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13287-026-05207-x","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:02:33Z","timestamp":1787094153000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy of multi-layered human iPS cell-derived cardiovascular cell sheets in a pacing-induced canine dilated cardiomyopathy model"],"prefix":"10.1186","volume":"17","author":[{"given":"Yu","family":"Shimoyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Kakuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiho","family":"Araki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyoe","family":"Komae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minoru","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun K.","family":"Yamashita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"5207_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-019-0084-1","author":"HP Schultheiss","year":"2019","unstructured":"Schultheiss HP, Fairweather D, Caforio ALP, Escher F, Hershberger RE, Lipshultz SE, et al. Dilated cardiomyopathy. Nat Rev Dis Primers. 2019. https:\/\/doi.org\/10.1038\/s41572-019-0084-1.","journal-title":"Nat Rev Dis Primers"},{"key":"5207_CR2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000155616.07901.35","author":"U K\u00fchl","year":"2005","unstructured":"K\u00fchl U, Pauschinger M, Noutsias M, Seeberg B, Bock T, Lassner D, et al. High prevalence of viral genomes and multiple viral infections in the myocardium of adults with idiopathic left ventricular dysfunction. Circulation. 2005. https:\/\/doi.org\/10.1161\/01.CIR.0000155616.07901.35.","journal-title":"Circulation"},{"key":"5207_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/s1388-9842(02)00010-7","author":"AL Caforio","year":"2002","unstructured":"Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002. https:\/\/doi.org\/10.1016\/s1388-9842(02)00010-7.","journal-title":"Eur J Heart Fail"},{"key":"5207_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.03.590","author":"AG Japp","year":"2016","unstructured":"Japp AG, Gulati A, Cook SA, Cowie MR, Prasad SK. The Diagnosis and Evaluation of Dilated Cardiomyopathy. J Am Coll Cardiol. 2016. https:\/\/doi.org\/10.1016\/j.jacc.2016.03.590.","journal-title":"J Am Coll Cardiol"},{"key":"5207_CR5","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-21-0001","author":"N Enzan","year":"2021","unstructured":"Enzan N, Matsushima S, Ide T, Kaku H, Tohyama T, Funakoshi K, et al. Clinical Characteristics and Contemporary Management of Patients With Cardiomyopathies in Japan\u3000- Report From a National Registry of Clinical Personal Records. Circ Rep. 2021. https:\/\/doi.org\/10.1253\/circrep.CR-21-0001.","journal-title":"Circ Rep"},{"key":"5207_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-77360-3","author":"K Hirono","year":"2024","unstructured":"Hirono K, Hata Y, Ichimata S, Nishida N, Imamura T, Asano Y, et al. Sarcomere gene variants did not improve cardiac function in pediatric patients with dilated cardiomyopathy from Japanese cohorts. Sci Rep. 2024. https:\/\/doi.org\/10.1038\/s41598-024-77360-3.","journal-title":"Sci Rep"},{"key":"5207_CR7","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-16-0976","author":"N Fukushima","year":"2017","unstructured":"Fukushima N, Ono M, Saiki Y, Sawa Y, Nunoda S, Isobe M. Registry Report on Heart Transplantation in Japan (June 2016). Circ J. 2017. https:\/\/doi.org\/10.1253\/circj.CJ-16-0976.","journal-title":"Circ J"},{"key":"5207_CR8","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.119.044924","author":"A Loupy","year":"2020","unstructured":"Loupy A, Coutance G, Bonnet G, Van Keer J, Raynaud M, Aubert O, et al. Identification and Characterization of Trajectories of Cardiac Allograft Vasculopathy After Heart Transplantation: A Population-Based Study. Circulation. 2020. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.119.044924.","journal-title":"Circulation"},{"key":"5207_CR9","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-21-0880","author":"M Ono","year":"2022","unstructured":"Ono M, Yamaguchi O, Ohtani T, Kinugawa K, Saiki Y, Sawa Y, et al. JCS\/JSCVS\/JATS\/JSVS 2021 Guideline on Implantable Left Ventricular Assist Device for Patients With Advanced Heart Failure. Circ J. 2022. https:\/\/doi.org\/10.1253\/circj.CJ-21-0880.","journal-title":"Circ J"},{"key":"5207_CR10","doi-asserted-by":"publisher","DOI":"10.1253\/circrep.CR-66-0014","author":"M Asase","year":"2024","unstructured":"Asase M, Watanabe T, Takegami M, Nishimura K, Nin K, Fukushima NCORRIGENDUM. Impact of Different Therapeutic Strategies With Left Ventricular Assist Devices on Health-Related Quality of Life During Prolonged Device-Based Support. Circ Rep. 2024. https:\/\/doi.org\/10.1253\/circrep.CR-66-0014.","journal-title":"Circ Rep"},{"key":"5207_CR11","doi-asserted-by":"publisher","first-page":"1029984","DOI":"10.3389\/fcvm.2022.1029984","volume":"9","author":"M Ando","year":"2022","unstructured":"Ando M, Ono M. Concomitant or late aortic valve intervention and its efficacy for aortic insufficiency associated with continuous-flow left ventricular assist device implantation. Front Cardiovasc Med. 2022;9:1029984. https:\/\/doi.org\/10.3389\/fcvm.2022.1029984.","journal-title":"Front Cardiovasc Med"},{"key":"5207_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.healun.2016.03.014","author":"JZ Willey","year":"2016","unstructured":"Willey JZ, Gavalas MV, Trinh PN, Yuzefpolskaya M, Reshad Garan A, Levin AP, et al. Outcomes after stroke complicating left ventricular assist device. J Heart Lung Transpl. 2016. https:\/\/doi.org\/10.1016\/j.healun.2016.03.014.","journal-title":"J Heart Lung Transpl"},{"key":"5207_CR13","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8120570","author":"C Hoeeg","year":"2020","unstructured":"Hoeeg C, Frljak S, Qayyum AA, Vrtovec B, Kastrup J, Ekblond A, et al. Efficacy and Mode of Action of Mesenchymal Stem Cells in Non-Ischemic Dilated Cardiomyopathy: A Systematic Review. Biomedicines. 2020. https:\/\/doi.org\/10.3390\/biomedicines8120570.","journal-title":"Biomedicines"},{"key":"5207_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/cells10030641","author":"D Zhu","year":"2021","unstructured":"Zhu D, Cheng K. Cardiac Cell Therapy for Heart Repair: Should the Cells Be Left. Out? Cells. 2021. https:\/\/doi.org\/10.3390\/cells10030641.","journal-title":"Out? Cells"},{"key":"5207_CR15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003918","author":"S Miyagawa","year":"2017","unstructured":"Miyagawa S, Domae K, Yoshikawa Y, Fukushima S, Nakamura T, Saito A, et al. Phase I Clinical Trial of Autologous Stem Cell-Sheet Transplantation Therapy for Treating Cardiomyopathy. J Am Heart Assoc. 2017. https:\/\/doi.org\/10.1161\/JAHA.116.003918.","journal-title":"J Am Heart Assoc"},{"key":"5207_CR16","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2021.11.008","author":"H Tani","year":"2022","unstructured":"Tani H, Tohyama S, Kishino Y, Kanazawa H, Fukuda K. Production of functional cardiomyocytes and cardiac tissue from human induced pluripotent stem cells for regenerative therapy. J Mol Cell Cardiol. 2022. https:\/\/doi.org\/10.1016\/j.yjmcc.2021.11.008.","journal-title":"J Mol Cell Cardiol"},{"key":"5207_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1182209","author":"T Kawamura","year":"2023","unstructured":"Kawamura T, Ito Y, Ito E, Takeda M, Mikami T, Taguchi T, et al. Safety confirmation of induced pluripotent stem cell-derived cardiomyocyte patch transplantation for ischemic cardiomyopathy: first three case reports. Front Cardiovasc Med. 2023. https:\/\/doi.org\/10.3389\/fcvm.2023.1182209.","journal-title":"Front Cardiovasc Med"},{"key":"5207_CR18","doi-asserted-by":"publisher","DOI":"10.1002\/stem.1089","author":"H Masumoto","year":"2012","unstructured":"Masumoto H, Matsuo T, Yamamizu K, Uosaki H, Narazaki G, Katayama S, et al. Pluripotent stem cell-engineered cell sheets reassembled with defined cardiovascular populations ameliorate reduction in infarct heart function through cardiomyocyte-mediated neovascularization. Stem Cells. 2012. https:\/\/doi.org\/10.1002\/stem.1089.","journal-title":"Stem Cells"},{"key":"5207_CR19","doi-asserted-by":"publisher","DOI":"10.1038\/srep16842","author":"T Matsuo","year":"2015","unstructured":"Matsuo T, Masumoto H, Tajima S, Ikuno T, Katayama S, Minakata K, et al. Efficient long-term survival of cell grafts after myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci Rep. 2015. https:\/\/doi.org\/10.1038\/srep16842.","journal-title":"Sci Rep"},{"key":"5207_CR20","doi-asserted-by":"publisher","DOI":"10.1016\/j.actbio.2011.04.013","author":"K Hayashi","year":"2011","unstructured":"Hayashi K, Tabata Y. Preparation of stem cell aggregates with gelatin microspheres to enhance biological functions. Acta Biomater. 2011. https:\/\/doi.org\/10.1016\/j.actbio.2011.04.013.","journal-title":"Acta Biomater"},{"key":"5207_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjon.2021.09.038","author":"H Osada","year":"2021","unstructured":"Osada H, Kawatou M, Fujita D, Tabata Y, Minatoya K, Yamashita JK, et al. Therapeutic potential of clinical-grade human induced pluripotent stem cell-derived cardiac tissues. JTCVS Open. 2021. https:\/\/doi.org\/10.1016\/j.xjon.2021.09.038.","journal-title":"JTCVS Open"},{"key":"5207_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/s11259-007-0005-8","author":"FA Recchia","year":"2007","unstructured":"Recchia FA, Lionetti V. Animal models of dilated cardiomyopathy for translational research. Vet Res Commun. 2007. https:\/\/doi.org\/10.1007\/s11259-007-0005-8.","journal-title":"Vet Res Commun"},{"key":"5207_CR23","doi-asserted-by":"publisher","unstructured":"Shirasaka T, Miyagawa S, Fukushima S, Kawaguchi N, Nakatani S, Daimon T et al. Skeletal Myoblast Cell Sheet Implantation Ameliorates Both Systolic and Diastolic Cardiac Performance in Canine Dilated Cardiomyopathy Model. Transplantation. 2016; https:\/\/doi.org\/10.1097\/TP.0000000000001014","DOI":"10.1097\/TP.0000000000001014"},{"key":"5207_CR24","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.00471.2008","author":"K Qanud","year":"2008","unstructured":"Qanud K, Mamdani M, Pepe M, Khairallah RJ, Gravel J, Lei B, et al. Reverse changes in cardiac substrate oxidation in dogs recovering from heart failure. Am J Physiol Heart Circ Physiol. 2008. https:\/\/doi.org\/10.1152\/ajpheart.00471.2008.","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"5207_CR25","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1374","author":"M Nakagawa","year":"2008","unstructured":"Nakagawa M, Koyanagi M, Tanabe K, Takahashi K, Ichisaka T, Aoi T, et al. Generation of induced pluripotent stem cells without Myc from mouse and human fibroblasts. Nat Biotechnol. 2008. https:\/\/doi.org\/10.1038\/nbt1374.","journal-title":"Nat Biotechnol"},{"key":"5207_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0201650","author":"M Ishigami","year":"2018","unstructured":"Ishigami M, Masumoto H, Ikuno T, Aoki T, Kawatou M, Minakata K, et al. Human iPS cell-derived cardiac tissue sheets for functional restoration of infarcted porcine hearts. PLoS ONE. 2018. https:\/\/doi.org\/10.1371\/journal.pone.0201650.","journal-title":"PLoS ONE"},{"key":"5207_CR27","first-page":"52","volume":"22","author":"R Venkataramanan","year":"1990","unstructured":"Venkataramanan R, Jain A, Cadoff E, Warty V, Iwasaki K, Nagase K, et al. Pharmacokinetics of FK 506: preclinical and clinical studies. Transpl Proc. 1990;22:52\u20136.","journal-title":"Transpl Proc"},{"key":"5207_CR28","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199101000-00003","author":"KP Platz","year":"1991","unstructured":"Platz KP, Sollinger HW, Hullett DA, Eckhoff DE, Eugui EM, Allison AC. RS-61443\u2013a new, potent immunosuppressive agent. Transplantation. 1991. https:\/\/doi.org\/10.1097\/00007890-199101000-00003.","journal-title":"Transplantation"},{"key":"5207_CR29","unstructured":"Fox J, Boutchet-Valat M, Rcmdr. R Commander. R package version 2.7-1, 2020. 2022."},{"issue":"6","key":"5207_CR30","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1038\/s41374-020-0406-7","volume":"100","author":"H Matsunari","year":"2020","unstructured":"Matsunari H, Honda M, Watanabe M, Fukushima S, Suzuki K, Miyagawa S, et al. Pigs with \u03b4-sarcoglycan deficiency exhibit traits of genetic cardiomyopathy. Lab Invest. 2020;100(6):887\u201399. https:\/\/doi.org\/10.1038\/s41374-020-0406-7.","journal-title":"Lab Invest"},{"key":"5207_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2006.01.024","author":"H Hata","year":"2006","unstructured":"Hata H, Matsumiya G, Miyagawa S, Kondoh H, Kawaguchi N, Matsuura N, et al. Grafted skeletal myoblast sheets attenuate myocardial remodeling in pacing-induced canine heart failure model. J Thorac Cardiovasc Surg. 2006. https:\/\/doi.org\/10.1016\/j.jtcvs.2006.01.024.","journal-title":"J Thorac Cardiovasc Surg"},{"key":"5207_CR32","unstructured":"Todo S, Podesta L, ChapChap P, Kahn D, Pan CE, Ueda Y et al. Orthotopic liver transplantation in dogs receiving FK-506. Transplant Proc. 1987;19(5 Suppl 6):64\u2009\u2013\u20097."},{"key":"5207_CR33","doi-asserted-by":"publisher","DOI":"10.1097\/TP.0b013e3181e6f201","author":"S Miyagawa","year":"2010","unstructured":"Miyagawa S, Saito A, Sakaguchi T, Yoshikawa Y, Yamauchi T, Imanishi Y, et al. Impaired myocardium regeneration with skeletal cell sheets\u2013a preclinical trial for tissue-engineered regeneration therapy. Transplantation. 2010. https:\/\/doi.org\/10.1097\/TP.0b013e3181e6f201.","journal-title":"Transplantation"},{"key":"5207_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/srep06716","author":"H Masumoto","year":"2014","unstructured":"Masumoto H, Ikuno T, Takeda M, Fukushima H, Marui A, Katayama S, et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci Rep. 2014. https:\/\/doi.org\/10.1038\/srep06716.","journal-title":"Sci Rep"},{"issue":"1","key":"5207_CR35","doi-asserted-by":"publisher","first-page":"5","DOI":"10.2174\/1566523216666160119094143","volume":"16","author":"S Miyagawa","year":"2016","unstructured":"Miyagawa S, Fukushima S, Imanishi Y, Kawamura T, Mochizuki-Oda N, Masuda S, et al. Building A New Treatment For Heart Failure-Transplantation of Induced Pluripotent Stem Cell-derived Cells into the Heart. Curr Gene Ther. 2016;16(1):5\u201313. https:\/\/doi.org\/10.2174\/1566523216666160119094143.","journal-title":"Curr Gene Ther"},{"key":"5207_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/86498","author":"AA Kocher","year":"2001","unstructured":"Kocher AA, Schuster MD, Szabolcs MJ, Takuma S, Burkhoff D, Wang J, et al. Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function. Nat Med. 2001. https:\/\/doi.org\/10.1038\/86498.","journal-title":"Nat Med"},{"key":"5207_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/nm.2736","author":"MN Islam","year":"2012","unstructured":"Islam MN, Das SR, Emin MT, Wei M, Sun L, Westphalen K, et al. Mitochondrial transfer from bone-marrow-derived stromal cells to pulmonary alveoli protects against acute lung injury. Nat Med. 2012. https:\/\/doi.org\/10.1038\/nm.2736.","journal-title":"Nat Med"},{"key":"5207_CR38","doi-asserted-by":"publisher","DOI":"10.1177\/09636897221148457","author":"D Mori","year":"2023","unstructured":"Mori D, Miyagawa S, Kawamura T, Yoshioka D, Hata H, Ueno T, et al. Mitochondrial Transfer Induced by Adipose-Derived Mesenchymal Stem Cell Transplantation Improves Cardiac Function in Rat Models of Ischemic Cardiomyopathy. Cell Transpl. 2023. https:\/\/doi.org\/10.1177\/09636897221148457.","journal-title":"Cell Transpl"},{"key":"5207_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s13287-024-04123-2","author":"PH Rayat","year":"2025","unstructured":"Rayat PH, Sani M. Mesenchymal stem cells derived exosomes: a new era in cardiac regeneration. Stem Cell Res Ther. 2025. https:\/\/doi.org\/10.1186\/s13287-024-04123-2.","journal-title":"Stem Cell Res Ther"},{"key":"5207_CR40","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.3389\/fphys.2019.01049","volume":"10","author":"H Yu","year":"2019","unstructured":"Yu H, Wang Z. Cardiomyocyte-Derived Exosomes: Biological Functions and Potential Therapeutic Implications. Front Physiol. 2019;10:1049. https:\/\/doi.org\/10.3389\/fphys.2019.01049.","journal-title":"Front Physiol"},{"key":"5207_CR41","doi-asserted-by":"publisher","first-page":"1268814","DOI":"10.3389\/fcvm.2023.1268814","volume":"10","author":"JD McCully","year":"2023","unstructured":"McCully JD, Del Nido PJ, Emani SM. Mitochondrial transplantation: the advance to therapeutic application and molecular modulation. Front Cardiovasc Med. 2023;10:1268814. https:\/\/doi.org\/10.3389\/fcvm.2023.1268814.","journal-title":"Front Cardiovasc Med"},{"issue":"1","key":"5207_CR42","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/s13287-025-04193-w","volume":"16","author":"P Hassanpour","year":"2025","unstructured":"Hassanpour P, Sadeghsoltani F, Saghebasl S, Boroumand S, Khanicheragh P, Tafti SHA, et al. Mitochondrial transplantation for cardioprotection and induction of angiogenesis in ischemic heart disease. Stem Cell Res Ther. 2025;16(1):54. https:\/\/doi.org\/10.1186\/s13287-025-04193-w.","journal-title":"Stem Cell Res Ther"}],"container-title":["Stem Cell Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13287-026-05207-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13287-026-05207-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T23:02:35Z","timestamp":1787094155000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13287-026-05207-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5207"],"URL":"https:\/\/doi.org\/10.1186\/s13287-026-05207-x","relation":{},"ISSN":["1757-6512"],"issn-type":[{"value":"1757-6512","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,19]]},"assertion":[{"value":"3 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Ethics approval and consent to participate for using of iPSC. Name of the institutional approval committee or unit; Foundation for iPS Cell Research and Application (CiRA, Kyoto University). Title of the approved project; Preclinical development toward a clinical trial of HLA-homozygous iPSC-derived cardiac lineage cells and cellular constructs. Approval number; G1025-8. Date of Approval; 2022.05.31. Ethics approval and consent to participate regarding the use of human cells (iPSCs). Human induced pluripotent stem cells (iPSCs; QHJI0104s) used in this study were provided by the Center for iPS Cell Research and Application (CiRA), Kyoto University. Written informed consent for the use of these cells in clinical and preclinical research was obtained from the donor by the providing institution. The present study did not involve direct contact with human participants, and no additional informed consent was required. Ethics approval and consent to participate for animal experiment. Name of the institutional approval committee or unit; Nissei Bilis\u2019s Institutional Ethics Committee. Title of the approved project; Efficacy evaluation study of IHJ-301 in a canine pacing-induced heart failure model. Approval number: 2023\u2009\u2212\u2009183 for animal experiment and 2024FEB09 for genetic modification experiment. Date of Approval: 2024.02.20.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y.S. is an employee of iHeart Japan Corporation. K.K. and K.A. are directors of iHeart Japan Corporation, Kyoto, Japan. J.K.Y. is a founder, equity holder, and scientific adviser of iHeart Japan Corporation, and is a co-inventor on multiple patents related to IHJ\u2011301.The Department of Cellular and Tissue Communications, Graduate School of Medicine, The University of Tokyo is an endowed department supported by TAKARA Bio Inc. (Shiga, Japan).The remaining authors (H.K. and M.O.) declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AI-assisted tools were used solely for language editing to improve clarity and grammar. The authors take full responsibility for the content of the manuscript, including the accuracy of the data and the integrity of the conclusions.","order":4,"name":"Ethics","label":"Generative AI and AI-assisted technologies in the writing process","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"263"}}